Description
💊 Dapagliflozin 5mg + Metformin 1000mg + Sitagliptin 50mg Tablets
Triple Pathway Control – Smarter Management of Type 2 Diabetes
Overview
Dapagliflozin 5mg + Metformin 1000mg + Sitagliptin 50mg is an oral antidiabetic fixed-dose combination (FDC) used for managing Type 2 Diabetes Mellitus (T2DM) in adults. It combines three complementary agents, each with a distinct mechanism of action, to provide enhanced glucose control. This combination is particularly useful in patients who require treatment intensification but want to minimize the number of pills.
This triple therapy addresses insulin resistance, hepatic glucose production, postprandial spikes, and renal glucose reabsorption — offering a comprehensive approach to glycemic control.
Pharmacological Class
- Dapagliflozin – SGLT2 Inhibitor
- Metformin – Biguanide
- Sitagliptin – DPP-4 Inhibitor
Mechanism of Action
🔹 Dapagliflozin (5mg)
- Inhibits SGLT2 in the kidneys
- Increases glucose excretion through urine
- Supports weight loss and mild blood pressure reduction
🔹 Metformin (1000mg)
- Suppresses hepatic glucose production
- Enhances insulin sensitivity
- Slows intestinal glucose absorption
🔹 Sitagliptin (50mg)
- Inhibits DPP-4 enzyme
- Increases incretin hormones, promoting insulin release and reducing glucagon secretion
- Improves post-meal glucose levels
Together, these drugs act through three different but synergistic mechanisms, offering superior glycemic control with a low risk of hypoglycemia.
Indications
- Type 2 Diabetes Mellitus in adults
- Patients with inadequate glycemic control on dual therapy (e.g., Metformin + Sitagliptin or Metformin + Dapagliflozin)
- Ideal for patients needing treatment intensification in a single tablet
How to Use
- Dosage: As directed by the physician, usually once or twice daily
- Administration: Take with meals to reduce gastrointestinal side effects (from metformin)
- Swallow the tablet whole with water. Do not crush or chew
- Take at the same time each day for best results
Drink plenty of water throughout the day to reduce dehydration risk (from dapagliflozin).
Benefits
- Controls fasting and postprandial blood glucose
- May assist with weight loss
- Low risk of hypoglycemia when used alone
- Simplifies therapy with triple action in one tablet
- May provide cardiorenal benefits in select patients
Possible Side Effects
- Dapagliflozin: Urinary infections, increased urination, dehydration
- Metformin: Nausea, diarrhea, abdominal discomfort (usually temporary)
- Sitagliptin: Headache, upper respiratory infections, rare allergic reactions
- Rare but serious: Lactic acidosis (metformin), ketoacidosis (dapagliflozin), pancreatitis (sitagliptin)
Precautions
- Not for use in Type 1 diabetes or diabetic ketoacidosis
- Avoid in patients with moderate to severe renal impairment
- Use with caution in elderly and dehydrated patients
- Monitor renal function, liver enzymes, and HbA1c periodically
- Inform doctor if pregnant or planning pregnancy
Storage
- Store below 30°C in a dry place
- Keep out of reach of children
- Protect from heat and moisture
When to Contact a Doctor
- Persistent nausea, vomiting, or abdominal pain
- Signs of urinary or genital infection
- Fatigue, muscle pain, or breathing difficulty
Conclusion
Dapagliflozin 5mg + Metformin 1000mg + Sitagliptin 50mg is a smart, triple-acting oral combination for effective blood sugar control in Type 2 Diabetes. It simplifies treatment while offering additional benefits like weight and blood pressure management, all with a low hypoglycemia risk.
